{"schema_version":"secwatch.filing_event.v1","accession":"0000875045-25-000027","form_type":"8-K","ticker":"BIIB","cik":"0000875045","company_name":"BIOGEN INC.","filed_at":"2025-07-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.539939+00:00","generated_at":"2026-05-18T09:24:01.824045+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Biogen expects Q2 2025 charge of $46M for IPR&D, reducing EPS by ~$0.26","bullets":["Pre-tax acquired IPR&D, upfront and milestone expense of ~$46M in Q2 2025.","GAAP and non-GAAP diluted EPS impact of approximately ($0.26) per share.","Charge covers upfront and milestone payments from collaboration/license agreements.","Biogen does not forecast such expenses due to uncertainty in timing and magnitude.","Q2 2025 results not finalized; subject to closing procedures."],"urls":{"canonical":"https://secwatch.observer/filing/0000875045-25-000027","json":"https://secwatch.observer/filing/0000875045-25-000027.json","markdown":"https://secwatch.observer/filing/0000875045-25-000027.md","text":"https://secwatch.observer/filing/0000875045-25-000027.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/875045/000087504525000027/0000875045-25-000027-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/875045/000087504525000027/biib-20250707.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T09:24:01.824045+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}